Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018441 | 0.92 | CXCR4 (0.36) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6690903 | 0.91 | CXCR4 (0.41) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6018171 | 0.89 | HDAC1 (0.35) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6018508 | 0.88 | HDAC1 (0.35) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6019642 | 0.87 | HDAC1 (0.34) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6018701 | 0.87 | HDAC1 (0.34) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6018156 | 0.85 | GCGR (0.34) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6689236 | 0.78 | CXCR4 (0.40) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6018874 | 0.78 | CXCR4 (0.39) | HDAC1HDAC3HDAC2NCOR2FNTA | |
| SCHEMBL6019678 | 0.77 | CXCR4 (0.46) | HDAC1HDAC3HDAC2NCOR2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | HDAC1 651/4885HDAC3 2307/4885HDAC2 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.